BIOMARKER:

HER-2 mutation

A1 | Sensitive

A2 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

A2 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Solid Tumor

Lung Adenocarcinoma

Colorectal Cancer

Gastric Cancer

Breast Cancer

Lung Cancer

Urothelial Cancer

Estrogen Receptor Positive Breast Cancer

Biliary Tract Cancer

Cholangiocarcinoma

Gastroesophageal Junction Adenocarcinoma

HER2 Positive Breast Cancer

Cervical Cancer

Squamous Cell Carcinoma of Head and Neck

Thymic Carcinoma

Esophageal Cancer

Uterine Cancer

Triple Negative Breast Cancer

Gallbladder Cancer

Hormone Receptor Positive Breast Cancer

Ovarian Cancer

Gastroesophageal Cancer

ado-trastuzumab emtansine

HER-2 mutation|Non Small Cell Lung Cancer|ado-trastuzumab emtansine

HER-2 mutation|Lung Adenocarcinoma|ado-trastuzumab emtansine

neratinib

HER-2 mutation|Breast Cancer|neratinib

HER-2 mutation|Estrogen Receptor Positive Breast Cancer|neratinib

HER-2 mutation|Biliary Tract Cancer|neratinib

HER-2 mutation|Cholangiocarcinoma|neratinib

HER-2 mutation|HER2 Positive Breast Cancer|neratinib

HER-2 mutation|Cervical Cancer|neratinib

HER-2 mutation|Gallbladder Cancer|neratinib

HER-2 mutation|Ovarian Cancer|neratinib

HER-2 mutation|Gastroesophageal Cancer|neratinib

pyrotinib

HER-2 mutation|Non Small Cell Lung Cancer|pyrotinib

HER-2 mutation|Solid Tumor|pyrotinib

HER-2 mutation|Colorectal Cancer|pyrotinib

HER-2 mutation|Gastric Cancer|pyrotinib

HER-2 mutation|Lung Cancer|pyrotinib

HER-2 mutation|Thymic Carcinoma|pyrotinib

SHR-A1811

HER-2 mutation|Non Small Cell Lung Cancer|SHR-A1811

HER-2 mutation|Colorectal Cancer|SHR-A1811

HER-2 mutation|Gastric Cancer|SHR-A1811

HER-2 mutation|Urothelial Cancer|SHR-A1811

HER-2 mutation|Biliary Tract Cancer|SHR-A1811

HER-2 mutation|Gastroesophageal Junction Adenocarcinoma|SHR-A1811

trastuzumab + pertuzumab

HER-2 mutation|Non Small Cell Lung Cancer|trastuzumab + pertuzumab

HER-2 mutation|Solid Tumor|trastuzumab + pertuzumab

HER-2 mutation|Lung Adenocarcinoma|trastuzumab + pertuzumab

HER-2 mutation|Lung Cancer|trastuzumab + pertuzumab

HER-2 mutation|Biliary Tract Cancer|trastuzumab + pertuzumab

HER-2 mutation|Uterine Cancer|trastuzumab + pertuzumab

trastuzumab + neratinib

HER-2 mutation|Non Small Cell Lung Cancer|trastuzumab + neratinib

HER-2 mutation|Estrogen Receptor Positive Breast Cancer|trastuzumab + neratinib

HER-2 mutation|Triple Negative Breast Cancer|trastuzumab + neratinib

HER-2 mutation|Hormone Receptor Positive Breast Cancer|trastuzumab + neratinib

fam-trastuzumab deruxtecan-nxki

HER-2 mutation|Non Small Cell Lung Cancer|fam-trastuzumab deruxtecan-nxki

HER-2 mutation|Solid Tumor|fam-trastuzumab deruxtecan-nxki

HER-2 mutation|Breast Cancer|fam-trastuzumab deruxtecan-nxki

HER-2 mutation|Colorectal Cancer|fam-trastuzumab deruxtecan-nxki

BI 1810631

HER-2 mutation|Non Small Cell Lung Cancer|BI 1810631

HER-2 mutation|Solid Tumor|BI 1810631

HER-2 mutation|Cholangiocarcinoma|BI 1810631

HER-2 mutation|Esophageal Cancer|BI 1810631

afatinib

HER-2 mutation|Non Small Cell Lung Cancer|afatinib

HER-2 mutation|Lung Adenocarcinoma|afatinib

HER-2 mutation|Lung Cancer|afatinib

HER-2 mutation|Urothelial Cancer|afatinib

HER-2 mutation|Cervical Cancer|afatinib

BDTX-189

HER-2 mutation|Solid Tumor|BDTX-189

ribociclib

HER-2 mutation|Breast Cancer|ribociclib

tarloxotinib bromide

HER-2 mutation|Non Small Cell Lung Cancer|tarloxotinib bromide

HER-2 mutation|Solid Tumor|tarloxotinib bromide

disitamab vedotin

HER-2 mutation|Non Small Cell Lung Cancer|disitamab vedotin

HER-2 mutation|Gastric Cancer|disitamab vedotin

bevacizumab

HER-2 mutation|Non Small Cell Lung Cancer|bevacizumab

HER-2 mutation|Ovarian Cancer|bevacizumab

trastuzumab

HER-2 mutation|Non Small Cell Lung Cancer|trastuzumab

HER-2 mutation|Gastric Cancer|trastuzumab

HER-2 mutation|Cholangiocarcinoma|trastuzumab

HER-2 mutation|HER2 Positive Breast Cancer|trastuzumab

pembrolizumab + margetuximab

HER-2 mutation|Gastroesophageal Junction Adenocarcinoma|pembrolizumab + margetuximab

pyrotinib + inetetamab

HER-2 mutation|Non Small Cell Lung Cancer|pyrotinib + inetetamab

neratinib + temsirolimus

HER-2 mutation|Non Small Cell Lung Cancer|neratinib + temsirolimus

U3-1402

HER-2 mutation|Non Small Cell Lung Cancer|U3-1402

cetuximab + ISU104

HER-2 mutation|Squamous Cell Carcinoma of Head and Neck|cetuximab + ISU104

KN046 + KN026

HER-2 mutation|Solid Tumor|KN046 + KN026

pembrolizumab

HER-2 mutation|Non Small Cell Lung Cancer|pembrolizumab

pemetrexed

HER-2 mutation|Lung Adenocarcinoma|pemetrexed

rivoceranib + pyrotinib

HER-2 mutation|Non Small Cell Lung Cancer|rivoceranib + pyrotinib

enfortumab vedotin-ejfv

HER-2 mutation|Urothelial Cancer|enfortumab vedotin-ejfv

regorafenib

HER-2 mutation|Colorectal Cancer|regorafenib

ORIC-114

HER-2 mutation|Solid Tumor|ORIC-114

albumin-bound paclitaxel

HER-2 mutation|Non Small Cell Lung Cancer|albumin-bound paclitaxel

durvalumab + fam-trastuzumab deruxtecan-nxki

HER-2 mutation|Non Small Cell Lung Cancer|durvalumab + fam-trastuzumab deruxtecan-nxki

tucatinib

HER-2 mutation|Estrogen Receptor Positive Breast Cancer|tucatinib

dasatinib

HER-2 mutation|Ovarian Cancer|dasatinib

HER-2 mutation|Gastroesophageal Cancer|dasatinib

durvalumab

HER-2 mutation|Non Small Cell Lung Cancer|durvalumab

dasatinib + neratinib

HER-2 mutation|Ovarian Cancer|dasatinib + neratinib

HER-2 mutation|Gastroesophageal Cancer|dasatinib + neratinib

eFT226

HER-2 mutation|Solid Tumor|eFT226

lapatinib

HER-2 mutation|Cholangiocarcinoma|lapatinib

trastuzumab-pkrb

HER-2 mutation|HER2 Positive Breast Cancer|trastuzumab-pkrb

JBJ-08–178–01

HER-2 mutation|Non Small Cell Lung Cancer|JBJ-08–178–01

PD1 inhibitor

HER-2 mutation|Non Small Cell Lung Cancer|PD1 inhibitor

HER-2 mutation|Solid Tumor|PD1 inhibitor

PD-L1 inhibitor

HER-2 mutation|Non Small Cell Lung Cancer|PD-L1 inhibitor

Immunotherapy

HER-2 mutation|Non Small Cell Lung Cancer|Immunotherapy

HER-2 mutation|Lung Adenocarcinoma|Immunotherapy

Tyrosine kinase inhibitor

HER-2 mutation|Non Small Cell Lung Cancer|Tyrosine kinase inhibitor

Angiogenesis inhibitor

HER-2 mutation|Non Small Cell Lung Cancer|Angiogenesis inhibitor